LENSAR (LNSR) Stock Price, News & Analysis

Company Overview

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Key Stats

• Today's Range: $14.00 to $14.11
• 50-Day Range: $9.20 to $16.87
• 52-Week Range: $2.67 to $17.31
• Volume: 134,505 shs
• Average Volume: 63,461 shs
• Market Capitalization: $165.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Hold

LENSAR Stock Analysis - MarketRank™

LENSAR scored higher than 11% of companies evaluated by MarketBeat, and ranked 891st out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

LENSAR has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

LENSAR has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of LENSAR is -9.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LENSAR is -9.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LENSAR has a P/B Ratio of 4.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.52% of the float of LENSAR has been sold short.

Short Interest Ratio / Days to Cover

LENSAR has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LENSAR has recently increased by 31.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LENSAR does not currently pay a dividend.

Dividend Growth

LENSAR does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.52% of the float of LENSAR has been sold short.

Short Interest Ratio / Days to Cover

LENSAR has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LENSAR has recently increased by 31.87%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.85

News Sentiment

LENSAR has a news sentiment score of -0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for LENSAR this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for LNSR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added LENSAR to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LENSAR insiders have not sold or bought any company stock.

Percentage Held by Insiders

38.52% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LNSR Stock Analysis - Frequently Asked Questions

How have LNSR shares performed this year?

LENSAR's stock was trading at $8.94 at the beginning of 2025. Since then, LNSR shares have increased by 56.8% and is now trading at $14.02.
View the best growth stocks for 2025 here.

How were LENSAR's earnings last quarter?

LENSAR, Inc. (NASDAQ:LNSR) released its earnings results on Thursday, February, 27th. The company reported ($1.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $1.40. The firm earned $16.73 million during the quarter, compared to the consensus estimate of $14.95 million. LENSAR had a negative net margin of 34.03% and a negative trailing twelve-month return on equity of 49.02%.

How do I buy shares of LENSAR?

Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LENSAR own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LENSAR investors own include Arch Capital Group (ACGL), Aprea Therapeutics (APRE), Artelo Biosciences (ARTL), AstraZeneca (AZN), Baidu (BIDU), Cidara Therapeutics (CDTX) and The Carlyle Group (CG).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 4/03/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LNSR
• CIK: 1320350
• Web: www.lensar.com
• Phone: 888-536-7271
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +6.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,380,000.00
• Net Margins: -34.03%
• Pretax Margin: -34.03%
• Return on Equity: -49.02%
• Return on Assets: -21.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.37
• Quick Ratio: 2.10

Sales & Book Value

• Annual Sales: $53.49 million
• Price / Sales: 3.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.97 per share
• Price / Book: 4.75

Miscellaneous

• Outstanding Shares: 11,789,000
• Free Float: 7,141,000
• Market Cap: $166.22 million
• Optionable: Optionable
• Beta: 0.62